Antivirals Against SARS-CoV2 : Relevance to the Treatment of Alzheimer's Disease

A recent study in vitro has shown that a sulphated polysaccharide, a type of fucoidan, has potent antiviral activity against SARS-Cov2. If the antiviral action were successful also for COVID-19 patients, it would be enormously valuable against not only acute disease but also long-term mental effects, which might include Alzheimer's disease (AD). In a trial of AD patients, the apparent success of treatment with a polysaccharide, GV971, was suggested to result from antiviral action against herpes simplex virus type 1 (HSV1) in brain, a pathogen strongly implicated in AD, and that sulphation of GV971, making it fucoidan-like, might increase its putative antiviral action. These data indicate that treatment of AD patients might be very effective using valacyclovir, a conventional antiviral, which inhibits viral replication, together with a fucoidan, which blocks virus entry into cells.

Errataetall:

CommentOn: Cell Discov. 2020 Jul 24;6:50. - PMID 32714563

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:78

Enthalten in:

Journal of Alzheimer's disease : JAD - 78(2020), 3 vom: 29., Seite 905-906

Sprache:

Englisch

Beteiligte Personen:

Itzhaki, Ruth F [VerfasserIn]

Links:

Volltext

Themen:

Alzheimer’s disease
Antiviral
COVID-19
Comment
Fucoidans
Herpes simplex virus type 1
Journal Article
SARS-Cov2

Anmerkungen:

Date Completed 08.12.2020

Date Revised 05.01.2022

published: Print

CommentOn: Cell Discov. 2020 Jul 24;6:50. - PMID 32714563

Citation Status PubMed-not-MEDLINE

doi:

10.3233/JAD-200986

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM316436461